CCA CATO Associate Safety Reporting & Adverse Events 1 — Questions and Answers
Question 1: What is the definition of a Serious Adverse Event (SAE) in clinical trials?
- Any adverse event that causes mild discomfort
- An adverse event that results in death, is life-threatening, requires hospitalization, causes persistent disability, or is a congenital anomaly (Correct answer)
- An adverse event that requires dose reduction only
- Any event reported by the subject regardless of severity
Correct answer: An adverse event that results in death, is life-threatening, requires hospitalization, causes persistent disability, or is a congenital anomaly
An SAE is defined by regulatory criteria including death, life-threatening events, hospitalization, persistent disability, congenital anomaly, or other medically significant events.
Question 2: Within what timeframe must a fatal or life-threatening unexpected SUSAR (Suspected Unexpected Serious Adverse Reaction) be reported to regulatory authorities in the US under IND regulations?
- 24 hours
- 7 calendar days (Correct answer)
- 15 calendar days
- 30 calendar days
Correct answer: 7 calendar days
Fatal or life-threatening unexpected SUSARs must be reported to the FDA within 7 calendar days under IND regulations (21 CFR 312.32).
Question 3: What is the difference between 'causality assessment' and 'expectedness' in adverse event reporting?
- They are the same concept
- Causality assesses the relationship of the event to the investigational product; expectedness compares the event to what is described in the reference safety document (Correct answer)
- Causality is only assessed by the IRB; expectedness is assessed by the subject
- Expectedness refers to how common the event is in the general population
Correct answer: Causality assesses the relationship of the event to the investigational product; expectedness compares the event to what is described in the reference safety document
Causality determines if the adverse event is related to the IP, while expectedness compares the event to descriptions in the Investigator Brochure or labeling.
Question 4: Who at an investigative site is responsible for assessing causality of adverse events to the investigational product?
- The Clinical Research Associate (CRA)
- The sponsor's medical monitor
- The Principal Investigator or qualified sub-investigator (Correct answer)
- The IRB/IEC
Correct answer: The Principal Investigator or qualified sub-investigator
The Principal Investigator or a qualified sub-investigator is responsible for assessing the causal relationship between the IP and the observed adverse event.
Question 5: What action must the investigator take upon learning of a fatal SAE occurring in a study subject?
- Wait until the next monitoring visit to report it
- Report it to the sponsor immediately and to the IRB/IEC within required timeframes (Correct answer)
- Only notify the IRB if it was related to the IP
- File the event in the source documents and take no further immediate action
Correct answer: Report it to the sponsor immediately and to the IRB/IEC within required timeframes
Fatal SAEs must be reported to the sponsor immediately (often within 24 hours) and to the IRB/IEC within required timeframes per protocol and regulations.
Question 6: What is an 'Adverse Event of Special Interest' (AESI) in clinical trials?
- Any serious adverse event requiring hospitalization
- A scientifically or medically important event that may require special monitoring or reporting, as defined in the protocol (Correct answer)
- An adverse event caused exclusively by the comparator product
- An event that occurs only in pediatric subjects
Correct answer: A scientifically or medically important event that may require special monitoring or reporting, as defined in the protocol
An AESI is a pre-specified event of scientific or medical importance that requires special surveillance or expedited reporting as defined in the protocol.
CCA CATO Associate Safety Reporting & Adverse Events 1
What is the definition of a Serious Adverse Event (SAE) in clinical trials?